PCOS Has a New Name: What PMOS Means for Women

For years, many women living with Polycystic Ovarian Syndrome felt the name never fully reflected what they were experiencing.

The condition affected far more than ovaries or fertility. It could impact energy, metabolism, mood, weight regulation, skin, sleep, confidence and long term health, yet the name Polycystic Ovarian Syndrome often narrowed the conversation to cysts and reproductive health alone.

Now, following more than a decade of global collaboration involving patients, clinicians and researchers, a new name has officially been introduced.

Polyendocrine Metabolic Ovarian Syndrome

While the condition itself has not changed, the way it is being understood is evolving, and for many women, that matters.

Polyendocrine Metabolic Ovarian Syndrome shifts the conversation from cysts on ovaries to recognising the condition for what it has always been: a complex, whole body hormonal and metabolic condition.

Why was the name changed?

One of the biggest misconceptions around Polycystic Ovarian Syndrome was built into the name itself.

Many women diagnosed with Polycystic Ovarian Syndrome do not actually have ovarian cysts. In fact, the cysts referred to in the condition are actually immature follicles, and many women with the condition never develop ovarian cysts at all.

For years, patient organisations and healthcare professionals argued that the old name failed to reflect the true nature of the condition. By focusing heavily on ovaries and fertility, it overlooked the wider hormonal, metabolic and long term health impacts many women experience.

Experts increasingly recognise Polyendocrine Metabolic Ovarian Syndrome as a whole body endocrine and metabolic condition, rather than simply a reproductive or ovarian disorder.

The new name aims to better reflect that broader picture:

• Polyendocrine: because multiple hormone systems can be affected, not just one
• Metabolic: recognising the role insulin resistance and metabolic health can play
• Ovarian Syndrome: acknowledging reproductive health while recognising it is only one part of the condition

Importantly, this change was not made overnight. It followed:
• more than 22,000 survey responses globally
• collaboration with 56 patient and professional organisations
• years of advocacy led by women with lived experience

This was not simply a medical rebrand. It was a patient led push for more accurate understanding, recognition and care.

More than a fertility condition

Historically, conversations around Polycystic Ovarian Syndrome focused heavily on fertility and irregular periods. While those symptoms absolutely matter, they are only part of the story.

Many women living with Polyendocrine Metabolic Ovarian Syndrome also experience:
• insulin resistance
• increased hunger or cravings
• weight fluctuations
• fatigue
• acne or excess hair growth
• anxiety and low mood
• sleep difficulties
• increased long term health risks such as type 2 diabetes and cardiovascular disease

For some women, symptoms begin in adolescence. For others, the impact continues through perimenopause and beyond.

The shift to Polyendocrine Metabolic Ovarian Syndrome reflects a growing understanding that this is a whole body condition that can affect women across the lifespan, not only during their reproductive years.

Why this matters emotionally too

For many women, the new name feels validating.

Too often, women living with Polyendocrine Metabolic Ovarian Syndrome have described feeling dismissed, blamed or misunderstood. Some were told to just lose weight. Others experienced delays in diagnosis or found that care focused only on fertility, while symptoms affecting their daily lives were overlooked.

For many women, the new name feels like recognition that their symptoms were never just about weight or just about fertility.

Language shapes healthcare. It shapes research, awareness, education and clinical thinking.

When a condition is misunderstood, women can feel misunderstood too.

The move toward Polyendocrine Metabolic Ovarian Syndrome reflects a broader shift toward recognising women’s health more holistically, including the metabolic, hormonal and emotional impact of conditions that have historically been under recognised.

What does this mean for women on GLP 1 programmes?

At SheMed, around 8% of our members are living with Polycystic Ovarian Syndrome or Polyendocrine Metabolic Ovarian Syndrome, and many will recognise the experiences reflected in this evolving guidance.

One of the most important developments within the conversation is the growing recognition of the role metabolism and insulin resistance can play in the condition. For many women, challenges with weight regulation are not simply about willpower. They are closely linked to hormones, appetite signalling and metabolic health.

This is one reason GLP 1 medications are increasingly being discussed as part of broader metabolic support for some women living with Polyendocrine Metabolic Ovarian Syndrome.

However, medication is only one part of the picture.

Long term support may also include:
• nutrition
• movement
• sleep
• emotional wellbeing
• behavioural support
• ongoing clinical care tailored to the individual

There is no one size fits all experience of Polyendocrine Metabolic Ovarian Syndrome, and no single treatment approach works for everyone. But a more accurate understanding of the condition may help women access more joined up, compassionate and personalised care in the future.

What changes with the Polyendocrine Metabolic Ovarian Syndrome diagnosis?

For now, the name is changing, but the condition itself has not changed. The new name is designed to better reflect what clinicians and women with lived experience have long recognised: this is a complex hormonal and metabolic condition, not simply an ovarian or fertility issue.

The transition from Polycystic Ovarian Syndrome to Polyendocrine Metabolic Ovarian Syndrome is expected to happen gradually, with both names used alongside each other while guidance and clinical systems catch up.

Will diagnostic criteria change?

At this stage, the diagnostic approach is not expected to change overnight. Diagnosis is still based on recognised features of the condition, including irregular ovulation or periods, signs of higher androgen levels, and ovarian markers depending on age and clinical context.

What may change over time is the way clinicians talk about, screen for and manage the condition. The new name places more emphasis on the whole body picture, including metabolic health, insulin resistance, cardiovascular risk, mental wellbeing and long term support.

What does this mean for your treatment?

Your treatment should still be based on your symptoms, goals and health risks. For some women, the focus may be cycle regulation, skin symptoms or fertility. For others, it may be weight regulation, insulin resistance, metabolic health, mood, sleep or long term risk reduction.

The name change does not mean everyone needs a different treatment. But it may help encourage more holistic care, rather than care that focuses only on periods, ovaries or fertility.

GLP 1 vs Metformin for Polyendocrine Metabolic Ovarian Syndrome management

Metformin has traditionally been used in Polycystic Ovarian Syndrome to support insulin resistance and metabolic health, particularly where there are concerns around blood sugar, weight or diabetes risk.

GLP 1 medications are increasingly being discussed for some women with the condition, particularly where weight regulation and metabolic health are key concerns.

This does not mean one is automatically better than the other. Metformin and GLP 1 medications work differently, and the right option depends on your medical history, symptoms, goals, eligibility and clinician assessment.

For some women, neither may be appropriate. For others, one or both may be considered as part of a broader care plan.

What should you do if you have a Polycystic Ovarian Syndrome or Polyendocrine Metabolic Ovarian Syndrome diagnosis?

You do not need to panic or seek urgent changes because of the new name. Your diagnosis has not disappeared, and your symptoms remain valid.

It may be helpful to use this moment to review whether your care reflects the full picture of the condition, including metabolic health, emotional wellbeing, cycle health, skin symptoms, fertility goals and long term risk factors.

Should you ask your doctor to update your diagnosis?

You can ask your GP or clinician about the name change, but your medical records may not be updated immediately. There is expected to be a transition period where both terms are used.

A useful question to ask could be:

Given the change from Polycystic Ovarian Syndrome to Polyendocrine Metabolic Ovarian Syndrome, should we review my metabolic health, long term risks and current treatment plan?

How SheMed can support you

At SheMed, we recognise that many women living with this condition need more than a narrow focus on weight or fertility. Our programme can support eligible members with metabolic health, weight regulation, lifestyle support, clinical oversight and personalised guidance.

For members living with Polycystic Ovarian Syndrome or Polyendocrine Metabolic Ovarian Syndrome, this means looking at the whole picture: your symptoms, your goals, your health risks and the support you need to feel understood and cared for.

What happens next?

The transition from Polycystic Ovarian Syndrome to Polyendocrine Metabolic Ovarian Syndrome will happen gradually over the coming years, and both names are expected to be used alongside each other during that time. Updated international guidelines are also expected to follow.

Importantly, experts and patient groups have been clear that a new name alone will not solve every challenge overnight. There is still work to do around:
• awareness
• diagnosis
• research
• education
• access to care

But for many women, this feels like an important step forward.

A shift toward more accurate understanding, more holistic care, and greater recognition of the full reality of living with this condition.

‍

‍

‍